Nivolumab and pembrolizumab are anti-PD-1 antibodies, and atezolizumab and durvalumab are anti-PD-L1 antibodies that are capable of inhibiting the interaction between PD-1 and PD-L1, thereby inhibiting this pathway and enhancing immune-mediated tumor destruction. Here, PDCD1 is linked to neoplasm.